Business context and reporting period
The supplied filing is Park City Group, Inc.’s Form 10-K for the fiscal year ended June 30, 2012—not a ReposiTrak, Inc. filing or a report for 2011 Q4. Park City Group provides supply-chain and retail software, principally through subscriptions, with related licensing, support, maintenance and consulting services. ReposiTrak was a product initiative developed through a partnership; Global Supply Chain Systems, Inc. was formed to offer it.
Financial performance and position
| Metric | FY2012 | FY2011 |
|---|---|---|
| Revenue | $10.10 million | $10.75 million |
| Subscription revenue | $6.99 million | $6.55 million |
| Other revenue | $3.10 million | $4.20 million |
| Operating income (loss) | ($0.97 million) | $0.14 million |
| Net income (loss) | ($0.86 million) | ($0.21 million) |
| Net loss per common share | ($0.14) | ($0.09) |
| Cash from operating activities | $1.01 million | $1.45 million |
| Cash and cash equivalents at year-end | $1.11 million | $2.62 million |
| Working capital | ($2.35 million) | ($2.40 million) |
| Total assets / total liabilities | $11.94 million / $6.63 million | $13.98 million / $8.65 million |
| Total debt, as reported in selected financial data | $2.71 million | $4.89 million |
Cost of revenue and product support rose to $4.58 million, or 45.4% of revenue, from $4.03 million, or 37.5%. This implies gross margin declined to about 54.6% from 62.5%. Operating margin was approximately (9.6%) versus 1.3%. Financing cash outflow was $2.28 million, while investing cash outflow was $0.24 million. The company also paid $0.49 million in preferred dividends; preferred dividends declared totaled $0.83 million.
Material changes versus the prior year
- Revenue fell 6.1% as other revenue decreased 26.2%; subscription revenue grew 6.8%, but was partly offset by the non-renewal of a significant retail customer.
- The company moved from operating income to an operating loss, with higher support costs and depreciation and amortization contributing to the deterioration.
- Cash declined by $1.51 million. The company used $2.59 million for note and lease repayments, partly offset by $1.01 million of operating cash flow.
- Total liabilities declined, primarily following repayment of notes; however, working capital remained substantially negative.
Outlook, risks and unusual items
- Management said available cash and anticipated operating cash flow should fund operations and debt service for at least the next 12 months, while acknowledging that refinancing or additional financing may be needed and is not assured.
- Management expected revenue growth in fiscal 2013 and beyond from connecting suppliers to existing retail customers and from new retail relationships. No numerical revenue or earnings guidance was provided.
- After year-end, the company announced a three-year CVS Pharmacy service agreement (July 2012) and initial ReposiTrak implementations at a grocery retailer and wholesaler (August 2012). These are subsequent developments, not FY2012 results.
- Series B preferred stock carried a 12% cash dividend rate, rising to 15% after three years and 18% after five years. A Series A holder disputed the company’s calculation of whether its dividend rate should increase from 5% to 10%; management disagreed. The filing shows that the alternative calculation would have increased the common-shareholder loss by $172,427 and loss per share from $0.14 to $0.16.
- Key risks include continued losses, limited liquidity, debt repayment and refinancing, subscription renewals and customer concentration, competition, service interruptions or security breaches, and reliance on the CEO. The filing reports no pending or threatened legal proceedings.
- A September 2012 board-approved repurchase program authorized purchases of up to $2.0 million over two years, but did not require the company to buy any shares.
Investor verification priorities
- Confirm the issuer and period: the document is Park City Group, Inc.’s FY2012 10-K, despite the request metadata naming ReposiTrak, Inc. and 2011 Q4.
- Verify the company’s actual debt and credit-line maturities, refinancing status, and ability to fund operations given $1.11 million of cash and negative working capital.
- Reconcile debt disclosures: the filing’s interest-rate discussion describes the mix as 31% variable and 69% fixed, while its debt table assigns 69.3% to variable-rate debt and 30.7% to fixed-rate debt.
- Check the preferred-stock dividend dispute and its cash, dilution and per-share implications, including the high Series B dividend obligations.
- Confirm execution and revenue contribution from the CVS agreement, ReposiTrak implementations and the announced repurchase program.
- Resolve the filing’s inconsistent market-venue descriptions: the cover identifies the OTC Bulletin Board, while Item 5 says NYSE American.
The independent auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal-control effectiveness.